Trial Profile

A Phase 3, Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 26 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pegcetacoplan (Primary)
Indications Age-related macular degeneration
Focus Adverse reactions; Registrational
Acronyms GALE
Sponsors Apellis Pharmaceuticals

Most Recent Events

06 Mar 2025 Planned End Date changed from 1 Sep 2025 to 1 Sep 2026.
28 Feb 2025 According to an Apellis Pharmaceuticals media release, 48-month data presented at The Macula Society Annual Meeting in February 2025 .
09 Jul 2024 According to an Apellis Pharmaceuticals media release, data from this will be presented at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting to be held July 17 - 20 in Stockholm, Sweden.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com